Zentek Ltd. Common Stock (ZTEK) Stock Price

ZTEKStock

$0.54−15.38%52W

Market Cap$68.37M

P/E—

PEG Ratio—

Div yield—

Beta1.97

ZTEK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.93%

Price vs S&P 500 (4W)-20.49%

VGM Score29.17

Book Value / Share (Quarterly)$0.08

P/TBV (Annual)4.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)31.60%

Cash Flow / Share (Quarterly)$-0.04

Price vs S&P 500 (YTD)-25.47%

Gross Margin (TTM)-53.63%

Net Profit Margin (TTM)-5882.54%

EPS (TTM)$-0.07

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.07

Revenue Growth (5Y)134.13%

EPS (Annual)$-0.07

ROI (Annual)-65.07%

Gross Margin (Annual)-57.84%

Net Profit Margin (5Y Avg)-15038.91%

Cash / Share (Quarterly)$0.01

Revenue Growth QoQ (YoY)-95.48%

ROA (Last FY)-54.57%

Revenue Growth TTM (YoY)-80.97%

EBITD / Share (TTM)$-0.07

ROE (5Y Avg)-109.36%

Operating Margin (TTM)-6611.64%

Cash Flow / Share (Annual)$-0.04

P/B Ratio9.75x

P/B Ratio (Quarterly)7.74x

Net Income / Employee (Annual)$-413,626

EV / Revenue (TTM)127.75x

Net Interest Coverage (TTM)-97.32x

ROA (TTM)-45.44%

EPS Incl Extra (Annual)$-0.07

Current Ratio (Annual)1.25x

Quick Ratio (Quarterly)0.67x

3-Month Avg Trading Volume0.23M

52-Week Price Return-15.38%

Revenue / Employee (TTM)$7,055

Tangible BV / Share (Quarterly)$0.18

P/S Ratio (Annual)724.77x

Asset Turnover (Annual)0.05x

52-Week High$1.22

Operating Margin (5Y Avg)-15826.70%

EPS Excl Extra (Annual)$-0.07

CapEx CAGR (5Y)-12.47%

Tangible BV CAGR (5Y)6.60%

26-Week Price Return0.00%

Quick Ratio (Annual)0.92x

13-Week Price Return-6.10%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)1.00x

Enterprise Value$86.71M

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-15.07%

Revenue / Employee (Annual)$7,055

Inventory Turnover (Annual)0.59x

Pretax Margin (Annual)-5882.54%

Cash / Share (Annual)$0.00

3-Month Return Std Dev97.30%

Gross Margin (5Y Avg)-425.16%

Net Income / Employee (TTM)$-413,626

ROE (Last FY)-68.07%

Net Interest Coverage (Annual)-97.32x

EPS Basic Excl Extra (Annual)$-0.07

Receivables Turnover (TTM)5.73x

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.07

Receivables Turnover (Annual)1.16x

ROI (TTM)-54.69%

P/S Ratio (TTM)724.77x

Pretax Margin (5Y Avg)-15038.91%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.22

Price vs S&P 500 (52W)-33.94%

Year-to-Date Return-13.48%

5-Day Price Return-7.23%

EPS Normalized (Annual)$-0.07

ROA (5Y Avg)-62.94%

Net Profit Margin (Annual)-5882.54%

Month-to-Date Return-18.95%

Cash Flow / Share (TTM)$-0.09

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-6611.64%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-92.76%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-0.07

P/TBV (Quarterly)6.09x

P/B Ratio (Annual)11.39x

Inventory Turnover (TTM)0.57x

Pretax Margin (TTM)-5882.54%

Book Value / Share (Annual)$0.10

Price vs S&P 500 (13W)-8.05%

Beta1.97x

Revenue / Share (TTM)$0.00

ROE (TTM)-61.26%

52-Week Low$0.37

vGradeF

gGradeD

mGradeD

vgmGradeD

ZTEK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2022	Feb 10, 2023	-$0.02	-$0.02	+0.00%(+$0.00)
Q3 2022	Nov 14, 2022	-$0.02	-$0.03	-33.33%(-$0.01)
Q2 2022	Aug 5, 2022	-$0.03	-$0.04	-25.00%(-$0.01)
Q1 2022	Jun 30, 2022	-$0.02	-$0.04	-100.00%(-$0.02)

ZTEK Analyst Recommendations

Jun 2023

Jul 2023

Aug 2023

Sep 2023

4.22

Industry Peers — Industrial Chemicals(8)

Symbol	Value Score	Growth Score	Momentum Score	Price
ZTEKZentek Ltd. Common Stock	F	D	D	$0.54
ESIElement Solutions Inc.	D	B	C	$34.93
CBTCabot Corporation	B	C	C	$83.65
WDFCWd-40 Co	D	B	C	$217.17
FTKFlotek Industries, Inc.	D	B	B	$23.93
ASPIASP Isotopes Inc. Common Stock	C	A	D	$3.88
OECOrion S.A.	B	D	C	$6.34
ARQArq, Inc. Common Stock	B	C	D	$2.16
FSIFlexible Solutions International, Inc.	C	C	C	$5.80

About Zentek Ltd. Common Stock

Zentek Ltd is a biotech company developing antimicrobial technologies for infectious disease prevention and treatment. Its lead product, ZENGuard, is a patent-pending coating with 99% antimicrobial efficacy against pathogens including COVID-19. The company is also advancing pharmaceutical applications of its proprietary compounds to address therapeutic opportunities in infectious diseases.